193 related articles for article (PubMed ID: 36580460)
1. Elucidating the effect of iron acquisition systems in Klebsiella pneumoniae on susceptibility to the novel siderophore-cephalosporin cefiderocol.
Daoud L; Al-Marzooq F; Moubareck CA; Ghazawi A; Collyns T
PLoS One; 2022; 17(12):e0277946. PubMed ID: 36580460
[TBL] [Abstract][Full Text] [Related]
2. High efficacy and enhanced synergistic activity of the novel siderophore-cephalosporin cefiderocol against multidrug-resistant and extensively drug-resistant Klebsiella pneumoniae from inpatients attending a single hospital in the United Arab Emirates.
Daoud L; Al-Marzooq F; Ghazawi A; Anes F; Collyns T
J Infect Public Health; 2023 Dec; 16 Suppl 1():33-44. PubMed ID: 37953111
[TBL] [Abstract][Full Text] [Related]
3. Characterisation of cefiderocol-non-susceptible Acinetobacter baumannii isolates from Taiwan.
Yamano Y; Ishibashi N; Kuroiwa M; Takemura M; Sheng WH; Hsueh PR
J Glob Antimicrob Resist; 2022 Mar; 28():120-124. PubMed ID: 34958997
[TBL] [Abstract][Full Text] [Related]
4. Extreme resistance to the novel siderophore-cephalosporin cefiderocol in an extensively drug-resistant Klebsiella pneumoniae strain causing fatal pneumonia with sepsis: genomic analysis and synergistic combinations for resistance reversal.
Daoud L; Allam M; Collyns T; Ghazawi A; Saleem A; Al-Marzooq F
Eur J Clin Microbiol Infect Dis; 2023 Nov; 42(11):1395-1400. PubMed ID: 37828413
[TBL] [Abstract][Full Text] [Related]
5.
Zhao J; Pu D; Li Z; Liu X; Zhang Y; Wu Y; Zhang F; Li C; Zhuo X; Lu B; Cao B
Antimicrob Agents Chemother; 2023 Dec; 67(12):e0073523. PubMed ID: 38014944
[TBL] [Abstract][Full Text] [Related]
6. Reduced susceptibility mechanism to cefiderocol, a siderophore cephalosporin, among clinical isolates from a global surveillance programme (SIDERO-WT-2014).
Kohira N; Hackel MA; Ishioka Y; Kuroiwa M; Sahm DF; Sato T; Maki H; Yamano Y
J Glob Antimicrob Resist; 2020 Sep; 22():738-741. PubMed ID: 32702396
[TBL] [Abstract][Full Text] [Related]
7. In vitro activity of cefiderocol against ceftazidime-avibactam susceptible and resistant KPC-producing Enterobacterales: cross-resistance and synergistic effects.
Bianco G; Boattini M; Comini S; Iannaccone M; Bondi A; Cavallo R; Costa C
Eur J Clin Microbiol Infect Dis; 2022 Jan; 41(1):63-70. PubMed ID: 34462816
[TBL] [Abstract][Full Text] [Related]
8. Catecholate siderophore receptor CirA impacts cefiderocol susceptibility in Klebsiella pneumoniae.
Lan P; Lu Y; Jiang Y; Wu X; Yu Y; Zhou J
Int J Antimicrob Agents; 2022 Oct; 60(4):106646. PubMed ID: 35918032
[TBL] [Abstract][Full Text] [Related]
9. Siderophore-mediated iron acquisition by
Kumar A; Chakravorty S; Yang T; Russo TA; Newton SM; Klebba PE
J Bacteriol; 2024 May; 206(5):e0002424. PubMed ID: 38591913
[TBL] [Abstract][Full Text] [Related]
10.
Abdul-Mutakabbir JC; Nguyen L; Maassen PT; Stamper KC; Kebriaei R; Kaye KS; Castanheira M; Rybak MJ
Antimicrob Agents Chemother; 2021 Aug; 65(9):e0264620. PubMed ID: 34125590
[TBL] [Abstract][Full Text] [Related]
11. Proteomic Investigation of the Antibacterial Mechanism of Cefiderocol against Escherichia coli.
Du GF; Dong Y; Fan X; Yin A; Le YJ; Yang XY
Microbiol Spectr; 2022 Oct; 10(5):e0109322. PubMed ID: 35980225
[TBL] [Abstract][Full Text] [Related]
12. Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli.
Zhanel GG; Golden AR; Zelenitsky S; Wiebe K; Lawrence CK; Adam HJ; Idowu T; Domalaon R; Schweizer F; Zhanel MA; Lagacé-Wiens PRS; Walkty AJ; Noreddin A; Lynch Iii JP; Karlowsky JA
Drugs; 2019 Feb; 79(3):271-289. PubMed ID: 30712199
[TBL] [Abstract][Full Text] [Related]
13. In vitro antibacterial activities of cefiderocol against Gram-negative clinical strains isolated from China in 2020.
Kohira N; Hackel MA; Oota M; Takemura M; Hu F; Mizuno H; Sahm DF; Yamano Y
J Glob Antimicrob Resist; 2023 Mar; 32():181-186. PubMed ID: 36513320
[TBL] [Abstract][Full Text] [Related]
14. Acinetobacter baumannii response to cefiderocol challenge in human urine.
Nishimura B; Escalante J; Tuttobene MR; Subils T; Mezcord V; Pimentel C; Georgeos N; Pasteran F; Rodriguez C; Sieira R; Actis LA; Tolmasky ME; Bonomo RA; Ramirez MS
Sci Rep; 2022 May; 12(1):8763. PubMed ID: 35610334
[TBL] [Abstract][Full Text] [Related]
15. Cefiderocol: An Overview of Its
Yao J; Wang J; Chen M; Cai Y
Front Med (Lausanne); 2021; 8():741940. PubMed ID: 34950677
[TBL] [Abstract][Full Text] [Related]
16. Involvement of Fe uptake systems and AmpC β-lactamase in susceptibility to the siderophore monosulfactam BAL30072 in Pseudomonas aeruginosa.
van Delden C; Page MG; Köhler T
Antimicrob Agents Chemother; 2013 May; 57(5):2095-102. PubMed ID: 23422914
[TBL] [Abstract][Full Text] [Related]
17. In vitro activity of cefiderocol, a siderophore cephalosporin, against a recent collection of clinically relevant carbapenem-non-susceptible Gram-negative bacilli, including serine carbapenemase- and metallo-β-lactamase-producing isolates (SIDERO-WT-2014 Study).
Kazmierczak KM; Tsuji M; Wise MG; Hackel M; Yamano Y; Echols R; Sahm DF
Int J Antimicrob Agents; 2019 Feb; 53(2):177-184. PubMed ID: 30395986
[TBL] [Abstract][Full Text] [Related]
18.
Ito A; Sato T; Ota M; Takemura M; Nishikawa T; Toba S; Kohira N; Miyagawa S; Ishibashi N; Matsumoto S; Nakamura R; Tsuji M; Yamano Y
Antimicrob Agents Chemother; 2018 Jan; 62(1):. PubMed ID: 29061741
[TBL] [Abstract][Full Text] [Related]
19.
McElheny CL; Fowler EL; Iovleva A; Shields RK; Doi Y
Microbiol Spectr; 2021 Dec; 9(3):e0177921. PubMed ID: 34756080
[TBL] [Abstract][Full Text] [Related]
20. In vitro activity of the novel siderophore cephalosporin, cefiderocol, in Gram-negative pathogens in Europe by site of infection.
Candel FJ; Santerre Henriksen A; Longshaw C; Yamano Y; Oliver A
Clin Microbiol Infect; 2022 Mar; 28(3):447.e1-447.e6. PubMed ID: 34298176
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
